ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2934

Comparative Analysis of the Macrophage Glycolytic Machinery in Giant Cell Arteritis (GCA) and in Coronary Artery Disease (CAD)

Cornelia M. Weyand1, Ryu Watanabe2, Tsuyoshi Shirai3, Hui Zhang4, Gerald Berry5 and Jorg Goronzy6, 1Medicine: Immunology and Rheumatology, Stanford University, Stanford, CA, 2Medicine: Immunology/Rheumatology, Stanford University School of Medicine, Stanford, CA, 3Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan, 4Medicine: Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, 5Pathology, Stanford University School of Medicine, Stanford, CA, 6Medicine/Division of Immunology & Rheumatology, Stanford University School of Medicine, Stanford, CA

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: coronary artery disease, giant cell arteritis and metabolism, Macrophage

  • Tweet
  • Email
  • Print
Session Information

Date: Wednesday, November 8, 2017

Title: Vasculitis III: Pathogenesis

Session Type: ACR Concurrent Abstract Session

Session Time: 9:00AM-10:30AM

Background/Purpose: Macrophages are key effector cells in the vessel wall inflammation of the atherosclerotic plaque as well as in the intramural infiltrates of giant cell arteritis (GCA). The histomorphology of both diseases is distinct; GCA macrophages are arranged in granulomatous lesions and form giant cells, whereas plaque-residing macrophages facilitate lipid uptake and participate in a fibro-inflammatory reparative process. Whether the profile of inflammatory macrophage functions is comparable in both conditions and which signaling pathways drive macrophage activation in the vessel wall lesions is insufficiently understood.

Methods: Tissue-residing macrophages were analyzed in biopsies from atherosclerotic plaques and from GCA-affected temporal arteries. Monocyte-derived macrophages were generated from peripheral blood CD14+ precursor cells by differentiating the cells with M-CSF over a 5-day culture. Macrophages were stimulated with 100 U/ml IFN-γ and 100 ng/ml LPS. Patients were enrolled if they had (a) at least one documented myocardial infarct or (b) a temporal artery biopsy positive for GCA. Tissue transcriptomes and gene expression panels from macrophages were established by RT-PCR. Protein expression was examined by flow cytometry and by immunohistochemical staining of tissue sections.

Results: In macrophages from patients with CAD glucose transporters and enzymes of the glycolytic pathway were strongly upregulated (Glut1, HK2, GAPDH, PKM1, PGM1, HIF1α, and c-myc). Glucose and its breakdown product pyruvate directly controlled the production of inflammatory cytokines (IL-1b, IL-6) and regulated the expression of co-stimulatory (CD80, CD86) and co-inhibitory ligands (PD-L1). Most plaque-residing macrophages were PD-L1hi expressors. In contrast, the glycolytic machinery was not upregulated in GCA macrophages. Profiling for chemokines and cytokines revealed high expression of CXCL9, 10 and 11 in GCA macrophages, but the inflammatory cytokines IL-1, IL-6 and TNF were indistinguishable in GCA patients versus normal controls. Opposite to CAD macrophages, GCA macrophages were characterized by low expression of the co-inhibitory ligand PD-L1. Tissue-residing cells in temporal artery lesions also had the PD-L1low phenotype.

Conclusion: Signaling pathways driving the activation of macrophages in the atherosclerotic plaque and in GCA lesions are fundamentally different. CAD macrophages are characterized by a metabolic defect, over-utilize glucose and are functionally a hybrid between excess cytokine release and high expression of PD-L1. GCA macrophages are biased towards chemokine production. The low expression of the immuno-inhibitory ligand PD-L1 enables them to strongly promote T cell effector functions.


Disclosure: C. M. Weyand, None; R. Watanabe, None; T. Shirai, None; H. Zhang, None; G. Berry, None; J. Goronzy, None.

To cite this abstract in AMA style:

Weyand CM, Watanabe R, Shirai T, Zhang H, Berry G, Goronzy J. Comparative Analysis of the Macrophage Glycolytic Machinery in Giant Cell Arteritis (GCA) and in Coronary Artery Disease (CAD) [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/comparative-analysis-of-the-macrophage-glycolytic-machinery-in-giant-cell-arteritis-gca-and-in-coronary-artery-disease-cad/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/comparative-analysis-of-the-macrophage-glycolytic-machinery-in-giant-cell-arteritis-gca-and-in-coronary-artery-disease-cad/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology